EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSCHOG00000000427
Gene Symbol: GRIN2A
1 Cross references
295 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSCHOG00000003174
Gene Symbol: GRIN2B
1 Cross references
335 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSCHOG00000004802
Gene Symbol: GRIN3A
1 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSCHOG00000010043
Gene Symbol: GRIK1
1 Cross references
316 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSCHOG00000013943
Gene Symbol: GRIK2
1 Cross references
336 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSCHOG00000007699
Gene Symbol: GRIK4
1 Cross references
263 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSCHOG00000003025
Gene Symbol: GRM3
1 Cross references
213 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSCHOG00000011702
Gene Symbol: GRM5
1 Cross references
278 Possible Orthologues:

Glutaminase

Ensembl ID : ENSCHOG00000013854
Gene Symbol: GLS
1 Cross references
306 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSCHOG00000012869
Gene Symbol: GSK3B
1 Cross references
244 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor

Ensembl ID : ENSCHOG00000002763
Gene Symbol: GNRHR
1 Cross references
242 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSCHOG00000013451
Gene Symbol: GHRHR
1 Cross references
193 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).